How were Shire's earnings last quarter?

Shire plc (NASDAQ:SHPG) posted its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, topping analysts' consensus estimates of $3.58 by $0.28. The biopharmaceutical company earned $3.77 billion during the quarter. Shire had a trailing twelve-month return on equity of 12.70% and a net margin of 30.63%. Shire's revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.63 earnings per share.

Is Shire a good dividend stock?

Shire (NASDAQ:SHPG) pays an annual dividend of $0.34 per share and currently has a dividend yield of 0.19%. The dividend payout ratio is 2.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SHPG will have a dividend payout ratio of 2.15% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for SHPG .

What other stocks do shareholders of Shire own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD) , Intel (INTC) , Merck & Co., Inc. (MRK) , Cisco Systems (CSCO) , Walt Disney (DIS) , Johnson & Johnson (JNJ) , Pfizer (PFE) , Starbucks (SBUX) and Exxon Mobil (XOM) .

NASDAQ:SHPG

Shire (SHPG) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free SHPG Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $179.20
▼
$179.20
50-Day Range: $179.20
▼
$179.20
52-Week Range: $123.73
▼
$182.47

Volume: N/A
Average Volume: 2.21 million shs
Market Capitalization: $54.71 billion

P/E Ratio: 11.83
Dividend Yield: 0.19%
Price Target: N/A

Stock Analysis

Get Shire alerts:

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About Shire Stock (NASDAQ:SHPG)

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

SHPG Stock News Headlines

October 15, 2023 | investing.com

SHPG Historical Data

March 30, 2023 | thestreet.com

Shire Stock Hits New 52-Week High (SHPG)

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

October 19, 2022 | bbc.com

Ethiopia's Tigray conflict: Nasa shows how a war zone faded from space - BBC

October 18, 2022 | bbc.com

Ethiopia civil war: Hyenas scavenge on corpses as Tigray forces retreat - BBC

October 18, 2022 | news.yahoo.com

Ethiopia civil war: Federal army seizes strategic city of Shire - Yahoo News

October 17, 2022 | washingtonpost.com

Ethiopian war in Tigray intensifies as government soldiers capture strategic Shire - The Washington Post

September 25, 2022 | dailymail.co.uk

Mum saves toddler with CPR in Sydney's Hills Shire: Triple-0 call revealed: Police Defibrillators - Daily Mail

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

September 15, 2022 | cbsnews.com

"Hobbit home" up for sale in River Falls, Wisconsin - CBS News

September 10, 2022 | npr.org

Fresh Air Weekend: Tennis great John McEnroe; Musician Amanda Shires - NPR

September 10, 2022 | npr.org

Best Of: John McEnroe / Amanda Shires : Fresh Air - NPR

September 7, 2022 | npr.org

Amanda Shires : Fresh Air - NPR

September 5, 2022 | theguardian.com

MLB’s Art Shires: hitter, peacock, boaster, boxer and accused killer - The Guardian

September 1, 2022 | countrystandardtime.com

Amanda Shires - Take It Like A Man - Country Standard Time

August 10, 2022 | theguardian.com

Dreaming shires: how East Yorkshire shaped Tolkien’s Middle-earth fantasy - The Guardian

August 3, 2022 | npr.org

On 'Take It Like a Man,' Amanda Shires takes aim for the heavens - NPR

July 29, 2022 | theguardian.com

Amanda Shires: Take It Like a Man review – reimagining country strong - The Guardian

July 21, 2022 | nytimes.com

Amanda Shires Isn’t Letting Nashville, or Her Marriage, Off the Hook - The New York Times

July 18, 2022 | dailymail.co.uk

Cat ban in Australia: Bass Coast Shire near Melbourne to fine pet owners if feline is outdoors - Daily Mail

July 17, 2022 | dailymail.co.uk

Nathan Brown lists $1.62million waterfront home in Sydney for sale - Daily Mail

June 23, 2022 | yahoo.com

Country singer Amanda Shires explains why she told her abortion story: 'It's part of my character to speak up' - Yahoo Life

June 17, 2022 | dallasnews.com

Richardson retail and office center is latest commercial property sale - The Dallas Morning News

May 26, 2022 | dailymail.co.uk

'Flood refugee' races to spruce up Scott Morrison's Shire home as he leaves Kirriblli House - Daily Mail

May 10, 2022 | bizjournals.com

Ignite Entertainment opens Shires' Cafe downtown at City Club Apartments - Cincinnati Business Courier - The Business Journals

April 26, 2022 | law360.com

2nd Circ. Affirms Shire Sanctions In Pharma IP Fight - Law360

April 11, 2022 | afr.com

Sydney property: “There's money in the shire, it's crazy”, says agent who just sold a Cronulla home with no water views for $4.9 million - The Australian Financial Review

See More Headlines

Receive SHPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shire and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/26/2018
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SHPG
CUSIP: N/A
CIK: 936402
Web: www.shire.com
Phone: 353-1609-6000
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $15.15
Trailing P/E Ratio: 11.83
Forward P/E Ratio: 11.88
P/E Growth: 1.54
Net Income: $4.27 billion
Net Margins: 30.63%
Pretax Margin: N/A
Return on Equity: 12.70%
Return on Assets: 7.06%

Debt

Debt-to-Equity Ratio: 0.36
Current Ratio: 0.92
Quick Ratio: 0.51

Sales & Book Value

Annual Sales: $15.16 billion
Price / Sales: 3.61
Cash Flow: $22.71 per share
Price / Cash Flow: 7.89
Book Value: $119.43 per share
Price / Book: 1.50

Miscellaneous

Outstanding Shares: 305,280,000
Free Float: N/A
Market Cap: $54.71 billion
Optionable: Optionable
Beta: 0.87

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Flemming Ornskov M.P.H. (Age 60)
MBA, M.D., MPH, CEO, MD & Exec. Director
Mr. Thomas J. W. Dittrich (Age 54)
CFO & Director
Gisele Dion
Chief Accounting Officer
Mr. Matthew Walker (Age 54)
Head of Technical Operations
Dr. Andreas Busch Ph.D. (Age 55)
Head of R&D and Chief Scientific Officer

Key Competitors

View All Competitors

Should I Buy Shire Stock? SHPG Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Shire plc:

Shire plc has shown consistent growth in its stock price over the past year, indicating a positive trend.
The company has a strong institutional ownership percentage, which can provide stability and confidence to investors.
Recent developments in Shire plc's product pipeline show promising potential for future revenue growth.
Shire plc's average daily volume indicates active trading, providing liquidity for investors.
With a low short percentage of float, there is less speculative pressure on the stock price.

Cons

Investors should be bearish about investing in Shire plc for these reasons:

Shire plc's outstanding shares are currently at 0, which may raise concerns about the company's financial structure.
The company's float size is 0, potentially limiting the stock's liquidity and trading opportunities.
Shire plc's recent month-to-month change in shorted shares percentage indicates increased bearish sentiment among investors.
Days to cover ratio of 0.4 suggests a higher risk of short squeezes due to a relatively low number of days required to cover short positions.
The company's fifty-two week performance has been relatively flat, signaling potential stagnation in stock price movement.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Shire pros and cons to contact@marketbeat.com.

SHPG Stock Analysis - Frequently Asked Questions

How were Shire's earnings last quarter?: Shire plc (NASDAQ:SHPG) posted its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, topping analysts' consensus estimates of $3.58 by $0.28. The biopharmaceutical company earned $3.77 billion during the quarter. Shire had a trailing twelve-month return on equity of 12.70% and a net margin of 30.63%. Shire's revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.63 earnings per share.
Is Shire a good dividend stock?: Shire (NASDAQ:SHPG) pays an annual dividend of $0.34 per share and currently has a dividend yield of 0.19%. The dividend payout ratio is 2.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SHPG will have a dividend payout ratio of 2.15% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for SHPG.
What other stocks do shareholders of Shire own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Walt Disney (DIS), Johnson & Johnson (JNJ), Pfizer (PFE), Starbucks (SBUX) and Exxon Mobil (XOM).

This page (NASDAQ:SHPG) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Shire (SHPG) Stock Price, News & Analysis

About Shire Stock (NASDAQ:SHPG)

SHPG Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Should I Buy Shire Stock? SHPG Pros and Cons Explained

Pros

Cons

SHPG Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info